Thus, the discovery of potent dual-target inhibitors based on hCES1A and PL hold great potential for the development of remedies for treating related metabolic diseases such as hypertriglyceridaemia and obesity. This evidence concerns the gene PNLIP and obesity due to melanocortin 4 receptor deficiency.